Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 1 of 48
(https://www.aetna.com/)
Transplant Immune Cell Function Assays
Policy History
Last Review
10/27/2019
Effective: 01/09/2009
Next
Review: 08/27/2020
Review History
Definitions
Additional Information
Clinical Policy Bulletin
Notes
Number: 0773
Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB.
Aetna considers the ImmuKnow Assay, also known as the
Transplantation Immune Cell Function Assay (Cylex, Inc.,
Columbia, MD) medically necessary to adjudicate over
immunosuppression in subpopulations of transplant recipients
with co-morbid infection or cancer.
Aetna considers the ImmuKnow Assay experimental and
investigational for all other indications including any of the
following because of insufficient evidence of its effectiveness:
▪ For detection of cellular immune function in individuals
with renal cell carcinoma
▪ For identification of individuals at risk for rejection prior
to kidney, liver, lung, or any other solid organ transplant
▪ For management of individuals undergoing allogeneic
hematopoietic stem cell transplantation
▪ For management of individuals with inflammatory
bowel diseases (Crohn's disease and ulcerative colitis)
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 2 of 48
▪ For management of organ transplant rejection in
individuals undergoing immunosuppressive therapy
post solid organ transplant
▪ For monitoring the immune response following surgery
▪ For prediction of infection risk in individuals receiving
disease-modifying anti-rheumatic drugs
▪ For prediction of risk infection in individuals with lupus
nephritis.
Aetna considers the Pleximmune test experimental and
investigational for prediction of acute cellular rejection in
children with liver or intestine transplantation and all other
indications because its clinical value has not been established.
Aetna considers the T-SPOT.CMV test experimental and
investigational because its clinical value has not been
established.
Aetna considers gamma interferon response experimental and
investigational for measurement of the bioactivity of
immunosuppressive medications in lung transplantation
because its clinical value has not been established.
Aetna considers measurement of donor-derived cell-free DNA
(e.g., Viracor TRAC) experimental and investigational as a
biomarker for allograft rejection in solid organ transplantation
because its clinical value has not been established.
Background
Transplant recipients have an increased risk of infection due to
the necessary immunosuppression. Conversely, under
immunosuppression carries the risk of rejection. Biopsy of the
transplanted organ can confirm rejection and is sometimes
performed before symptoms develop. When organ rejection is
suspected, additional tests may be performed prior to organ
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 3 of 48
biopsy. Management of organ transplant rejection by an
immune cell function assay to assess the immune function of
the transplant recipients and to individualize therapy has been
proposed. It has also been investigated as a method of
identifying patients at risk for early acute kidney transplant
rejection prior to the actual kidney transplant.
In April 2002, the Food and Drug Administration (FDA) cleared
for marketing the Cylex Immune Cell Function Assay
(Cylex Inc., Columbia, MD) for the detection of cell mediated
immune response in populations undergoing
immunosuppressive therapy for organ transplant. According
to the 510(k) application submitted by the manufacturer to the
FDA, the test detects cell-mediated immunity in whole blood
after a 15 to 18 hour incubation with a stimulant (i.e.,
phytohemagglutinin). During incubation, increased adenosine
triphosphate (ATP) synthesis occurs within the cells that
respond to phytohemagglutinin. Concurrently, whole blood is
incubated in the absence of phytohemagglutinin for the
purpose of assessing basal ATP activity. Anti-CD4
monoclonal antibody coated magnetic particles are added to
immuno-select CD4 cells from both the stimulated and non-
stimulated cells. After washing the selected CD4 cells on a
magnet tray, a lysis reagent is added to release intracellular
ATP. Addition of luminescence reagent (luciferin/luciferase) to
the released ATP produces light measured by a luminometer,
which is proportional to the concentration of ATP. The
concentration of ATP (ng/ml) is calculated from a calibration
curve and compared to ATP level ranges to characterize the
cellular immune function of the sample.
Kowalski et al (2006) assessed the relative risks of infection
and rejection of 504 solid organ transplant recipients (heart,
kidney, kidney-pancreas, liver and small bowel) using the
ImmuKnow assay. Blood samples were taken from recipients
at various times post-transplant and compared with clinical
course (stable, rejection, infection). In this analysis, 39 biopsy-
proven cellular rejections and 66 diagnosed infections
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 4 of 48
occurred. Odds ratios of infection or rejection were calculated
based on measured immune response values. The authors
reported that a recipient with an immune response value of 25
ng/ml ATP was 12 times (95 % confidence interval [CI]: 4 to
36) more likely to develop an infection than a recipient with a
stronger immune response and that a recipient with an
immune response of 700 ng/ml ATP was 30 times (95 % CI: 8
to 112) more likely to develop a cellular rejection than a
recipient with a lower immune response value.
Thai et al (2006) compared pancreas recipient clinical states
(stable, rejection, infection) with T cell responses using the
ImmuKnow assay. Blood samples were taken from pancreas
recipients pre-transplant and at approximately 3-month
intervals post-transplant for analysis of T cell responses.
When possible, T cell responses were also quantified during
changes in clinical status (infection or rejection). A range of
100 to 300 ng/ml ATP was found in stable patients (mean 194
+/- 123, n = 51) with good graft function and no infection or
rejection. A low T cell response correlated highly with
infectious states. Fourteen patients with infections/post
transplant lymphoproliferative disease had a mean ATP of 48
ng/ml. Risk hazard analysis showed that patients with ATP
levels less than 100 ng/ml were 4 to 7 times more susceptible
to infection compared to stable patients. Four patients with
rejection showed a T cell response of 550 ng/ml ATP, which
was statistically significant compared to stable patients,
although the sampling numbers (n = 9) were too small to be
conclusive.
Cadillo-Chavez and colleagues (2006) reviewed the records of
64 kidney transplant patients for associations between ATP
levels and immunosuppression type, doses, and levels;
creatinine levels; white blood cell count; tissue typing;
preformed antibodies; as well as ATP levels on infection and
rejection, and changes in ATP levels with time. Of the 58
patients that had pre-transplant and post-transplant ATP levels
tested, the authors reported no association between ATP
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 5 of 48
levels and immunosuppression type, doses, or levels;
creatinine levels; white blood cell counts; HLA; and panel-
reactive antibody (p > 0.05). However, patients with moderate
or high pre-transplant ATP levels had more rejection episodes
(8/10) while patients with ATP levels in the low immune
response had more infections (6/11) (p < 0.001; relative risk
[RR] for rejection = 1.2; RR for infection = 4.4). The mean
ATP levels for rejection was 423.3 ng/ml versus 268.45 ng/ml
for infection and 277.15 ng/ml for no events (ANOVA, p =
0.0145). Although acute rejections occurred mostly above
300, this was not significant (p = 0.059; RR = 0.9). Infections
were more frequent with ATP under 300 (RR = 7.3) and
severe infection (e.g., endocarditis, meningitis, peritoneal
abscesses, pneumonia, etc) were more frequent under 200 (p
< 0.001). When pre-transplant values were compared with
post-transplant values at the second week, an increase
correlated with rejection (p < 0.001, RR = 15.3), while a
decrease did not correlate with the infection (p = 0.845, RR =
1.4). Patients who received anti-rejection treatment had a
decrease in their ATP levels at day 5 (p = 0.002).
Batal et al (2008) reported on a retrospective study that found
a correlation between decreased immune cell function test
results and active BK virus replication, but not with acute
rejection, in kidney transplant recipients. ImmuKnow assay
measurements were performed on 15 samples from 8 patients
with BK viremia, 38 samples from 25 patients with BK viruria,
and 243 samples from 148 patients with no BK viruria or
viremia. The mean +/- SD amounts of ATP released in these
3 groups were 102.9 +/- 58.6, 227.2 +/- 146.4, and 231.8 +/
150.8 ng/ml, respectively (p = 0.002, viremia versus all other
samples). The investigators reported that, within the viruria
group, lower immune cell function assay values were
associated with higher urinary viral load (p = 0.037). There
was no significant relationship, however, between immune cell
function test results and acute transplant rejection. The
investigators concluded that prospective studies are needed to
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 6 of 48
determine whether this assay can be used as a screening tool
to stratify patients by their ultimate risk of developing BK
viremia and BK virus nephropathy.
In a study of kidney transplant recipients, Serban et al (2009)
found that, although low ATP levels by ImmuKnow
assay identified patients at increased risk for infection, high
ATP values failed to correlate with rejection and did not justify
increased immunosuppression. The investigators assessed
the significance of immune cell function in 76 renal allograft
recipients after anti-thymocyte globulin induction and initiation
of maintenance immunosuppression. The investigators found
that the Immuknow assay yielded paradoxically high ATP
values during the first 3 months post-transplantation, despite
very low CD4+ counts. The investigators reported that high
ATP values were caused by peripheral blood myeloid cells, did
not predict rejection, and occurred primarily in transplant
recipients who received darbepoietin (p = 0.017). Over the
first 5 months post-transplantation, mean ATP activity
gradually decreased, whereas CD4+ counts slowly increased.
Low ATP values were predictive of infection (p = 0.002). The
investigators concluded that ImmuKnow results,
therefore need to be interpreted with caution in patients
receiving anti-thymocyte induction therapy; although low ATP
levels identified patients at increased risk for infection, high
ATP values failed to correlate with rejection and did not justify
increased immunosuppression.
A study by Bhorade et al (2008) found that the ImmuKnow
assay had high sensitivity but poor specificity for infection in
lung transplant recipients. The investigators identified the
level of functional immunity as measured by the ImmuKnow
assay in lung transplant recipients and correlated these values
with the dose and trough levels of immunosuppression as well
as other clinical parameters in these patients. The
investigators assessed the functional immune response in 143
sequential blood samples from 57 lung transplant recipients
using the ImmuKnow assay and reported that the average
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 7 of 48
ImmuKnow assay in stable lung transplant recipients was 244
+/- 138 ATP ng/ml and the median level was 236 ATP ng/ml
(range 5 to 669 ATP ng/ml), about 703 +/- 695 days after lung
transplantation. There was no correlation between ImmuKnow
levels and tacrolimus trough levels. Stepwise multiple
regression analysis identified African American race as an
independent predictor of ImmuKnow assay levels when age,
gender and underlying diagnosis were taken into account (p <
0.04). The investigators found that the ImmuKnow assay
levels were lower in infected lung transplant recipients
compared with non-infected recipients and increased with
treatment of these infections. Fifteen infected lung transplant
recipients had a lower ImmuKnow level at the time of their
infections as compared with stable lung transplant recipients
(111 +/- 83 versus 283 +/- 143 ATP ng/ml, respectively, p =
0.0001). Sixteen of the remaining 42 patients had low
ImmuKnow assay values (less than 225 ATP ng/ml), but did
not have active infection. The investigators found that, while
the sensitivity for infection of an ATP value of less than 225
ng/ml was 93 % in this study, the specificity was only 38 %. In
addition, the utility of ATP measurements was not assessed,
as only 2 recipients in the patient sample had rejection. The
authors concluded, "It remains unclear whether the ImmuKnow
assay reflects over-immunosuppressed individuals at risk of
infection or bone marrow suppression by infectious agents.
Further investigation will determine the role of the ImmuKnow
assay in tailoring immunosuppression in lung transplant
recipients."
Husain et al (2009) reported the correlation between Cylex
ImmuKnow (ng/ml ATP) values and various infectious
syndromes in a large prospective cohort of lung transplant
recipients. These investigators followed-up 175 lung
transplants that developed 129 infectious episodes. Multiple
logistic regression analysis was performed; generalized
estimating equations were used to determine the odds ratio
(OR) for infections. The median ImmuKnow values in
cytomegalovirus disease (49.3 ng/ml ATP), viral infection (70
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 8 of 48
ng/ml ATP), and bacterial pneumonia (92 ng/ml ATP) were
significantly different from stable state (174.8 ng/ml ATP). The
median ImmuKnow values of fungal disease (85 ng/ml ATP)
and tracheobronchitis (123 ng/ml ATP) had a tendency to be
lower than stable state (p = 0.10), whereas patients with fungal
colonization had comparable ImmuKnow values (167 versus
174.8 ng/ml ATP). Of the patients colonized with fungus who
subsequently developed fungal disease within 100 days, the
median value of ImmuKnow was significantly lower than in
those who did not develop fungal disease (22.5 versus 183.5
ng/ml ATP; p < 0.0001). Generalized estimating equation
regression analysis showed ImmuKnow values less than or
equal to 100 ng/ml ATP to be an independent predictor of
infections (OR of 2.81). The authors concluded that Cylex
ImmuKnow assay monitoring has the potential to identify the
patients at risk of developing infection and those colonized
with fungus that are at risk of developing disease.
Another study, published in abstract form, demonstrated a very
poor correlation between histologically proven rejection and
the ImmuKnow assay, with 87 % of the allograft rejection
episodes occurring in the setting of a low to moderate ATP
level (Huang et al, 2007).
Cabrera et al (2009) used the ImmuKnow assay to help
assess the etiology of abnormal liver function test results in
liver transplant recipients. Blood samples for the immune
functional assay were taken from 42 recipients prospectively at
various times post-transplant and compared with clinical and
histologic findings. In patients whose liver biopsy showed
evidence of cellular rejection, the immune response was noted
to be very high, whereas in those with active recurrence of
hepatitis C, the immune response was found to be very low.
This finding was found to be statistically significant (p <
0.0001). In those patients in whom there was no predominant
histologic features suggesting 1 entity over the other, the
immune response was higher than in those with aggressive
hepatitis C but lower than in those with cellular rejection. The
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 9 of 48
authors concluded that these data show the potential utility of
the ImmuKnow assay as a means of distinguishing hepatitis C
from cellular rejection and its potential usefulness as a marker
for outlining the progression of hepatitis C.
Macedo et al (2009) investigated the impact of Epstein-Barr
virus (EBV) load on T-cell immunity from pediatric
transplantation recipients, using clinically applicable tests for
improved assessment of T-cell immune competence. A total
of 35 asymptomatic pediatric thoracic transplantation patients
were categorized into 3 groups according to their EBV load
levels: (i) undetectable viral load (UVL), (ii) chronic low viral
load (LVL) and (iii) chronic high viral load (HVL). Global and
EBV-specific T-cell immunity were assessed by ATP release
using Cylex Immuknow and T Cell Memory assays. Patients
with UVL exhibited normal ATP release to Concanavalin A
(ConA) and phytohemagglutinin (PHA; 190 +/- 86 ng/ml, 328
+/- 163 ng/ml) and detectable EBV-specific (37 +/- 34 ng/ml)
ATP responses. Patients with LVL displayed significantly
stronger responses to ConA (373 +/- 174 ng/ml), PHA (498 +/
196 ng/ml) and EBV (152 +/- 179 ng/ml), when compared with
UVL or to HVL patients (ConA 185 +/- 114 ng/ml, PHA 318 +/
173 ng/ml, and EBV 33 +/- 42 ng/ml). Moreover, patients with
HVL displayed significant inverse correlation between CD4+
T-cell ATP levels and EBV loads. The authors concluded that
evaluation of global and EBV-specific T-cell immunity provides
a rapid assessment of patients' immune competence.
However, it is still unclear if selective over-suppressed ATP
release by CD4+ T cells reflects HVL patients at risk of post-
transplant lymphoproliferative disease. They stated that
further longitudinal studies will determine the importance of
Immuknow test in identifying asymptomatic HVL patients
vulnerable to EBV complications.
Rossano et al (2009) tested the hypothesis that the Cylex
ImmuKnow cell function assay (CICFA) is a clinically useful
test in pediatric heart transplant patients. All children
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 10 of 48
undergoing heart transplantation at the study center (1989 to
2006) for whom CICFA levels were obtained were reviewed.
The association of CICFA levels with episodes of acute
rejection (AR) and significant infections was determined.
Among 83 patients (34 girls, 41 %), 367 CICFA levels were
obtained (median of 4.0; interquartile range [IQR], 2.0 to 6.0
per patient). There were 26 episodes of AR in 17 patients (20
%) and 38 infections in 34 patients (41 %). CICFA levels were
similar among patients with AR at the time of the CICFA
measurement (median of 325 [IQR, 163 to 480] ATP ng/ml)
versus patients without AR (median of 330 [IQR, 227 to 441]
ATP ng/ml; p = 0.36). CICFA levels were similar among
patients with infections within 1 month of CICFA measurement
(median of 295 [IQR, 216 to 366] ATP ng/ml) and those
without infections (median of 330 [IQR, 226 to 453] ATP ng/ml;
p = 0.24). The authors concluded that the CICFA is not
predictive of AR or significant infections in pediatric heart
transplant patients. On the basis of the available evidence,
these investigators stated that this assay can not be
recommended as part of the routine management of pediatric
heart transplant patients.
Gupta et al (2008) reported that the ImmuKnow assay had
limited clinical utility as an adjunct to routine clinical evaluation
in assessing risk of infection or rejection in heart transplant
recipients. The authors performed a retrospective review of the
clinical course of all adult cardiac transplant recipients who
underwent an ImmuKnow assay at University of Texas
Southwestern Medical Center between January 2004 and
September 2007. The authors reported that 111 patients were
free of significant rejection or infection at the time of the
first ImmuKnow assay. Most patients (92 %) were more than 1
year post-transplant. Over the next 157 +/- 41 (mean +/- SD)
days, 2 patients had 3 episodes of rejection requiring therapy
and 7 patients had 8 infections requiring therapy.
The ImmuKnow responses ranged from 17 to 894 ng/ml. No
correlation was observed between the baseline ImmuKnow
response and subsequent risk of either infection or rejection
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 11 of 48
within 6 months. Lower white blood cell count and African
American ethnicity were correlated with a lower ImmuKnow
response. The authors concluded that the Cylex assay had
limited utility as an adjunct to routine clinical evaluation in
assessing risk of infection or rejection in cardiac transplant
recipients.
Gesundheit et al (2010) stated that following allogeneic
hematopoietic stem cell transplantation (alloHSCT),
immunosuppressed patients are susceptible to opportunistic
infections, and uncontrolled function of the graft can result in
graft-versus-host disease (GVHD). Accurate immune
monitoring may help early detection and treatment of these
severe complications. Between October 2005 and November
2007, a total of 170 blood samples were collected from 40
patients after alloHSCT in the Hadassah Hebrew University
Medical Center and from 13 healthy controls. These
researchers utilized the Cylex ImmuKnow assay for CD4 ATP
levels to compare known clinically immunocompromised
versus immunocompetent patients after alloHSCT. They also
compared the reconstitution of white blood cell (WBC) count to
the ImmuKnow results and clinical status. The patients'
clinical course correlated with the stratification of immune
response established by the ImmuKnow assay for solid organ
transplantation (immunocompetent versus
immunocompromised), and this often differed from their WBC
count. The authors concluded that the Cylex ImmuKnow
assay should be evaluated prospectively in clinical trials.
The American Society of Transplantation (AST) does not
mention the use of the Cylex Immune Cell Function assay in
its recommendations for the screening, monitoring and
reporting of infections complications in the evaluation of
recipients of organ transplantation (AST, 2006). Chon and
Brennan (2009) commented that there is no consensus on the
utility of the Immuknow assay in renal transplant
rejection other than in the research setting. Martinu et al
(2009) commented that "the data in lung transplantation are
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 12 of 48
scarce and not very promising to date", and that "the
ImmuKnow assay does not seem to have the potential to
differentiate between infection and rejection in lung transplant
recipients and, until more data becomes available, should not
be used clinically in this patient population."
Bennett et al (2010) noted that infection of a transplanted
kidney with the polyomavirus, BK, is associated with poor
allograft survival. In an attempt to prevent this transplant
complication, these investigators studied 144 consecutive
transplant recipients for the presence of BK infection with
plasma and urine polymer chain reaction (PCR) testing at 1, 2,
3, 6 and 12 months. Viruria alone was followed by serial
studies. If plasma PCR became positive at greater than 2.6
log copies, mycophenolate was reduced until there was no
detectable plasma viral load. Urine PCR was positive in 34
(24 %), while plasma PCR turned positive in 22 cases (15 %).
No patients developed viremia with less than 6.8 log copies in
the urine. Viremia resolved within 3 months or less in 20 of 22
patients after reduction of immunosuppression. Surveillance
biopsies at 2 and 6 months revealed no BK nephropathy.
Eight patients had acute rejection during reduced
immunosuppression; however, all of these reversed with pulse
steroids. Patient and graft survival at 1 year was 99 % and 98
%, respectively. Use of the cell-mediated immunity assay
(ImmuKnow) was not useful in identifying infected patients.
Kobashigawa and colleagues (2010) examined the utility of
ImmuKnow in heart transplant recipients. Between November
2005 and July 2008, a total of 296 heart transplant recipients
had a total of 864 immun monitoring (IM) assays performed at
2 weeks to 10 years post-transplant and were correlated with
infection and rejection events that occurred within 1 month
after IM testing. All patients received standard triple-drug
immunosuppressive therapy with tacrolimus, mycophenolate
mofetil and corticosteroids, without induction therapy. There
were 38 infectious episodes and 8 rejection episodes. The
average IM score was significantly lower during infection than
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 13 of 48
steady state (187 versus 280 ng ATP/ml, p < 0.001). The
average IM score was not significantly different during
rejection when compared with steady state (327 versus 280 ng
ATP/ml, p = 0.35). Interestingly, 3 of 8 rejection episodes
were antibody-mediated rejections and had hemodynamic
compromise and, for these, the mean IM score was
significantly higher than for steady-state patients (491 versus
280 ng ATP/ml, p < 0.001). The authors concluded that
ImmuKnow appears to predict infectious risk in heart
transplant patients. The association between high IM scores
and rejection risk is inconclusive due to the small number of
rejection episodes. They stated that further studies with larger
sample sizes for rejection episodes are needed.
Torio et al (2011) stated that the Cylex ImmuKnow assay
provides a rapid assessment of global immune function in
immunocompromised patients by measuring the global
immune responses of CD4 T cells from a whole-blood sample.
It may help to monitor the immune status of
immunosuppressed transplant patients. However, earlier
studies have shown that there is no consensus on the utility of
the ImmuKnow assay in renal transplant rejection. T-cell
activation was determined by measuring an increase of
intracellular ATP (iATP) from CD4 cells in 227 samples from
116 kidney transplant patients. The results were analyzed
regarding patient clinical status, namely, rejection, infection, or
stability. In addition, these researchers measured the
immunologic response of 108 healthy control subjects. There
were 24 infectious and 36 rejection episodes. Intracellular
ATP concentrations differed significantly between stable and
infected patients (180.5 +/- 55.2 versus 375.3 +/- 140.1 ng/ml;
p < 0.001) and between infected patients and control subjects
(180.5 +/- 55.2 versus 436.5 +/- 112 ng/ml; p < 0.001). No
correlation was observed between patients suffering an acute
rejection episode with this response. The authors concluded
that these findings confirmed that the ImmuKnow assay
identified transplant patients at risk for infection. It may
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 14 of 48
provide information to guide immunosuppressive therapy, but
the assay did not seem to have the potential to differentiate
subjects experiencing rejection.
De Paolis et al (2011) evaluated the value of ImmuKnow (IK),
a new tool to measure the net state of immune function among
renal transplant recipients, in correlation with clinical and
laboratory data among unselected renal transplant recipients.
A total of 49 recipients of mean age of 51 years were enrolled
and followed for 1 year after transplantation. All subjects
received the same immunosuppressive strategy with
basiliximab induction and tacrolimus, mycophenolate mofetil
and steroid maintenance therapy. Samples for IK were
collected before transplantation as well as at 7, 14, 21 and 42
days and after 3, 6, and 12 months. There were 54 samples
with IK less than 225 ng/ml, 201 samples with normal IK
values, and 135 samples with greater than 525 ng/ml. These
investigators divided recipients into 3 groups with respect to
their basal IK values: Group 1 (Gr1; IK less than 225 ng/ml);
Group 2 (Gr2; normal values of IK between 226 and 524
ng/ml); and Group 3 (Gr3; IK greater than 525 ng/ml). At 1
year, these investigators observed a significant difference
among IK values at the start and the end of the study: Gr1
versus Gr2, p < 0.0001; Gr2 versus Gr3, p < 0.06 and Gr 1
versus Gr 3, p < 0.01). They observed reduced IK values to
predict an increased risk of infection, particularly with
cytomegalovirus (CMV) replication while higher IK value did
not correlate with an increased risk of acute rejection
episodes. Reduction of serum creatine levels occurred within
1 year in all groups (p < 0.005), but there was a significant
difference between Gr 2 versus Grs 1 and 3 (p < 0.0001 and p
< 0.0005, respectively). There findings suggested that more
stable IK values were associated with clinical quiescence and
laboratory stability. The authors concluded that this
preliminary analysis showed a beneficial capacity of this assay
to represent the global depression of the immune system.
They noted that reduced IK values, as a sign of excessive
immunosuppressive therapy, were associated with an
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 15 of 48
increased risk of infection. They did not confirm the predictive
value of higher IK values for an increased risk of an acute
rejection episode.
Huskey et al (2011) retrospectively analyzed 1,330 ImmuKnow
assay values in 583 renal transplant recipients at a single
center from 2004 to 2009 and correlated these values with
episodes of opportunistic infections (OI) and acute rejection
(AR) in the subsequent 90 days. Assay values were
compared with a control population matched for age, gender,
and time post-transplantation. In patients with OI (n = 94),
there were no differences in prior mean assay values
compared with matched controls (386 versus 417 ng/ml, p =
0.24). In 47 patients with AR, again no differences were
detected in prior assay results (390 versus 432 ng/ml, p =
0.25) when compared with controls. "Low" values (less than or
equal to 225 ng/ml) lacked sensitivity and specificity as a
predictive test for subsequent OI, as did "strong" (greater than
or equal to 525 ng/ml) values as a predictive test for
subsequent AR. The authors concluded that these findings fail
to show an association between single time point ImmuKnow
assay values and the subsequent development of an adverse
event in the subsequent 90 days. The optimal use of the
ImmuKnow assay in kidney transplantation has yet to be
determined.
Cheng et al (2011) determine the utility of the ImmuKnow
assay in assessing the risk of infection, rejection, and tumor
recurrence in liver transplant recipients. Immune function, as
determined by the ImmuKnow assay, was used to monitor the
global immune status in 342 whole blood samples from 105
liver transplant recipients. The association between ATP value
and post-transplant tumor recurrence was evaluated in 60
hepato-cellular carcinoma (HCC) patients. The ATP value in
predicting tumor recurrence in other independent cohort of 92
recipients with HCC was analyzed prospectively. The mean
ATP values of liver transplant recipients with infection
(145.2 +/- 87.0 ng/ml) or acute rejection (418.9 +/- 169.5
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 16 of 48
ng/ml) were different from those with stable state (286.6 +/
143.9 ng/ml, p < 0.05). In recipients with HCC who developed
recurrent tumors, the values were significantly lower than
those without recurrence (137.8 +/- 66.4 versus 289 +/- 133.9
ng/ml, p < 0.01); the optimal threshold value to predict post-
transplant tumor recurrence was 175 ng/ml. Comparing with
the patients in lower immune group (ATP les than or equal
to 175 ng/ml), patients in the higher immune group
(ATP greater than 175 ng/ml) experienced significantly better
disease-free survival (p < 0.01). Multi-variate Cox regression
analysis showed the ATP value was an independent predictor
of HCC recurrence. The authors concluded that the
ImmuKnow assay has the potential to evaluate the risk of
infection and rejection in liver transplantation and to predict
post-transplant tumor recurrence in recipients with HCC.
Rodrigo and colleagues (2012) conducted a systematic
literature review to identify studies documenting the use of
ImmuKnow to monitor immune function in liver transplant
recipients until March 2012. Study quality was assessed by
using the Quality Assessment of Diagnostic Accuracy Studies
2 score. These investigators identified 5 studies to analyze
ImmuKnow performance in infection and 5 in acute rejection.
Pooled sensitivity, specificity, positive likelihood ratio,
diagnostic odds ratio and area under a summary receiver-
operating characteristic curve were 83.8 % (95 % CI: 78.5 % to
88.3 %), 75.3 % (95 % CI: 70.9 % to 79.4 %), 3.3 (95 % CI: 2.8
to 4.0), 14.6 (95 % CI: 9.6 to 22.3) and 0.824 +/- 0.034 for
infection and 65.6 % (95 % CI: 55.0 % to 75.1 %), 80.4 % (95
% CI: 76.4 % to 83.9 %), 3.4 (95 % CI: 2.4 to 4.7), 8.8 (95 %
CI: 3.1 to 24.8) and 0.835 +/- 0.060 for acute rejection.
Heterogeneity was low for infection and high for acute
rejection studies. The authors concluded that ImmuKnow test
is a valid tool to know the risk of further infection in adult liver
transplant recipients. Moreover, they stated that significant
heterogeneity across studies precludes concluding that
ImmuKnow identifies liver transplant patients at risk for
rejection.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 17 of 48
Shino et al (2012) hypothesized that the ImmuKnow assay can
be used to assess the immune function of lung transplant
recipients and identify those at risk of developing acute cellular
rejection and respiratory infection. Lung transplant recipients
at University of California Los Angeles between January 1,
2006 and December 31, 2009 received a bronchoscopy with
broncheo-alveolar lavage, transbronchial biopsy and
ImmuKnow values drawn at regular intervals as well as during
episodes of clinical deterioration. The recipient's clinical
condition at each time-point was classified as healthy, acute
cellular rejection, or respiratory infection. Mixed-effects
models were used to compare the ATP levels among these
groups, and odds ratios for rejection and infection were
calculated. The mean ATP level was 431 +/- 189 ng/ml for the
rejection group versus 377 +/- 187 ng/ml for the healthy group
(p = 0.10). A recipient with an ATP level greater than 525
ng/ml was 2.1 times more likely to have acute cellular rejection
(95 % CI: 1.1 to 3.8). Similarly, the mean ATP level was
323 +/- 169 ng/ml for the infection group versus 377 +/- 187
ng/ml for the healthy group (p = 0.03). A recipient with an ATP
level less than 225 ng/ml was 1.9 times more likely to have
respiratory infection (95 % CI: 1.1 to 3.3). However, the test
was associated with poor performance characteristics. It had
low sensitivity, specificity with an area under the receiver
operating characteristic curve of only 0.61 to diagnose
rejection and 0.59 to diagnose infection. The authors
concluded that the ImmuKnow assay appears to have some
ability to assess the overall immune function of lung transplant
recipients. However, this study does not support its use as a
reliable predictor of episodes of acute cellular rejection or
respiratory infection.
In a meta-analysis, Ling et al (2012) evaluated the
effectiveness of the Cylex ImmuKnow cell function assay
(CICFA) in identifying risks of infection and rejection post-
transplantation. After a careful review of eligible studies,
sensitivity, specificity, and other measures of the accuracy of
CICFA were pooled. Summary receiver operating
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 18 of 48
characteristic curves were used to represent the overall test
performance. A total of 9 studies met the inclusion criteria.
The pooled estimates for CICFA in identification of infection
risk were poor, with a sensitivity of 0.58 (95 % CI: 0.52 to
0.64), a specificity of 0.69 (95 % CI: 0.66 to 0.70), a positive
likelihood ratio of 2.37 (95 % CI: 1.90 to 2.94), a negative
likelihood ratio of 0.39 (95 % CI: 0.16 to 0.70), and a
diagnostic odds ratio of 7.41 (95 % CI: 3.36 to 16.34). The
pooled estimates for CICFA in identifying risk of rejection were
also fairly poor with a sensitivity of 0.43 (95 % CI: 0.34 to
0.52), a specificity of 0.75 (95 % CI: 0.72 to 0.78), a positive
likelihood ratio of 1.30 (95 % CI: 0.74 to 2.28), a negative
likelihood ratio of 0.96 (95 % CI: 0.85 to 1.07), and a
diagnostic odds ratio of 1.19 (95 % CI: 0.65 to 2.20). The
authors concluded that current evidence suggests that CICFA
is not able to identify individuals at risk of infection or
rejection. They stated that additional studies are still needed
to clarify the usefulness of this test for identifying risks of
infection and rejection in transplant recipients.
Akimoto et al (2013) examined the ability of the ImmuKnow
(assay to predict the risk of infection in rheumatoid arthritis
(RA) patients receiving synthetic or biological disease-
modifying anti-rheumatic drugs (DMARDs). The amount of
ATP produced by CD4+ cells in response to
phytohemagglutinin was measured in whole blood from 117
RA patients without infection versus 17 RA patients with
infection, and compared with results in 75 healthy
controls. The mean ATP level was significantly lower in
patients with infection compared to both healthy controls (p <
0.0005) and patients without infection (p = 0.040). Also, the
mean ATP level in patients without infection was significantly
lower than that in healthy controls (p = 0.012). There was no
correlation between the ATP level and the Disease Activity
Score in 28 joints. The authors concluded that the ImmuKnow
assay results may be effective in identifying RA patients at
increased risk of infection, but the results showed no
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 19 of 48
correlation with RA activity. They stated that larger studies
are needed to establish the clinical advantages of this assay in
RA treatment.
There is insufficient evidence of the effectiveness of the
ImmuKnow assay in the management of organ transplant
rejection in individuals undergoing immunosuppressive
therapy post solid organ transplant and for the identification of
individual risk for rejection prior to kidney or any other solid
organ transplant. Prospective clinical outcome studies are
needed to determine its role in the management of solid organ
or stem cell transplant recipients.
Lopez-Hoyos et al (2013) stated that ImmuKnow is an in-vitro
diagnosis method that uses patient samples of whole blood
polyclonally stimulated with phytohemagglutinin. It also
measures ATP production by CD4+ T cells. The test aims to
offer an objective and overall measurement of each
individual's cellular immune response. The assay was
designed with the idea of individually monitoring the
immunosuppression administered to transplant patients. At
the same time, it aims to help achieve a balance as a way of
avoiding immunosuppression excess and the associated
adverse effects (infections, cancer, etc.) or an
immunosuppression defect and the subsequent risk of allograft
rejection. The majority of studies that have evaluated its
clinical usefulness display great diversity in terms of patient
recruitment, the immunosuppressant treatment received, the
clinical variables analyzed and, above all, the time between
performing ImmuKnow and the evaluated clinical event. The
most consistent data showed that this assay on CD4+ T cell
functioning is useful for predicting the risk of infection in renal
transplant patients. However, its use as a rejection risk
indicator is unclear. Lastly, given the great variability of
immune response amongst individuals and that of existing
publications, it can be deduced that the isolated ImmuKnow
value does not have diagnostic capacity and only individual
serial monitoring could provide definitive assistance in clinical
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 20 of 48
decision making and immunosuppressant treatment changes.
Moreover, the authors stated that other aspects of ImmuKnow
application in the clinical routine, such as assay cycles, require
randomized prospective studies for more comprehensive
information.
Israeli et al (2013) noted that currently there is no standardized
non-invasive diagnostic tool for the evaluation of
immunological complications such as GVHD and for managing
the cellular immune function of the transplant recipient. The
ImmuKnow assay for cellular immune function monitoring has
been incorporated successfully into the clinical follow-up
routine of solid organ transplant recipients. These researchers
examined the relevance and potential contribution of immune
monitoring using the assay in the setting of HCT. They found
that ImmuKnow-level measurement can distinguish between
states of immune function quiescence and between events of
acute GVHD. ImmuKnow levels were significantly higher in
patients going through GVHD than the levels measured for the
same patients during immunological stability. Moreover, they
demonstrated a patient case where longitudinal monitoring
using the ImmuKnow assay provided a trustworthy depiction of
the patient's cellular immune function post-HCT. The authors
concluded that they provided evidence for the potential
contribution of the ImmuKnow assay for longitudinal
individualized cellular immune function monitoring of patients
following HCT. Moreover, they stated that further studies are
needed to establish the optimal practice for utilizing the assay
for this purpose.
Brandhorst et al (2013) stated that Crohn's disease (CD) and
ulcerative colitis (UC) are inflammatory bowel diseases (IBDs),
which are characterized by dysfunctional regulation of the
immune system. A number of immune modifying drugs are
used to treat CD and UC. Therapy is adjusted largely on the
bases of subjective reports of disease activity and non-specific
laboratory tests. Identification of a single or combination of
immune markers of disease activity could be useful to select
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 21 of 48
and monitor therapeutic responses. However, to-date no
reliable quantitative associations between IBD activity and
laboratory measures of immune function have been identified.
These investigators evaluated the usefulness of ImmuKnow as
a surrogate marker of IBD activity. Adult IBD patients with
either CD (n = 55, 27 males, mean, SD age = 38.5, 11.5 years)
or UC (n = 45, 24 males, mean, SD age = 41.7, 15.4 years)
were enrolled. Patients both in clinical remission and with
active disease provided responses to structured, validated
questionnaires (CDAI and HBI for CD patients and SCCAI for
UC patients) used to monitor IBD activity. Whole blood and
plasma samples were collected to quantify various markers of
disease status including routine cell counts and differentials
(CBCs), C-reactive protein (CRP), and albumin (Alb), as well
as CD4(+) immune response (ImmuKnow, n = 98). Results
were compared between all IBD patients as well as between
CD and UC subgroups. There was a good correlation
between the results of CDAI and HBI scores (r = 0.811, p <
0.01, Spearman-Rho), but HBI scores correlated slightly better
(r = 0.575, p < 0.001) than the CDAI's (r = 0.449, p = 0.001)
with CD patients' reported perception of their general
condition. Furthermore, CDAI and HBI scores categorized
12/55 versus 36/55 of CD patients respectively as having
active disease; SCCAI scores indicated that 25/45 of UC
patients had active disease. ImmuKnow results (in ng/ml of
ATP) were increased in 74/98 IBD subjects (greater than or
equal to 525 ng/ml, but were influenced by the use of systemic
corticosteroids (SCS) and infliximab. There were weak but
statistically significant Spearman-Rho correlations between Alb
concentrations and both CDAI (r = 0.413, p = 0.002) and HBI
(r = 0.325, p = 0.017) scores as well as between CRP values
and HBI scores (r = 0.331, p = 0.016). Correlations between
CRP and both CDAI and SCCAI scores and between Alb and
SCCAI scores were not significant and there were no
significant positive associations between any of the 3 clinical
scores and ImmuKnow results. The authors concluded that
CD4(+) immune responses (ImmuKnow results) were
significantly elevated in IBD patients whether or not they were
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 22 of 48
in clinical remission, but were influenced by treatment. There
were some significant correlations between the clinical scores
and CRP or Alb, but not with the CD4(+) results. Both other
clinical scoring systems, other measures of immune function,
and CD4(+) immune response changes over time should be
examined to see if this or other laboratory measures of
immune response are predictive of actual disease activity or
symptoms in CD or UC patients.
Wong et al (2014) stated that the ImmuKnow ICFA reports ex-
vivo CD4 lymphocyte activation to quantify
immunosuppression. Limited organ and age-specific data
exist for pediatric heart transplant recipients. These
investigators examined their normative values and ICFA's
association with rejection/infection. A total of 380 ICFAs from
58 heart transplant recipients (6.5/recipient) were studied
retrospectively. The median age at the time of their first ICFA
was 5.3 yrs (IQR 2.4 to 12.1 yrs). ICFA levels during
immunologic stability (n = 311) were a median of 305 (IQR:
172 to 483) and mean of 353 (S.D. ± 224) ng ATP/ml. ICFA
levels trended lower with advancing age. ICFA levels during
immunologic stability increased over time from transplant after
the first 6 months but were not correlated with calcineurin
inhibitor levels or the type used. There was no association
between ICFA values during stability and rejection (median of
368 ATP ng/ml; IQR 153 to 527) or infection (median of 293
ATP ng/ml; IQR 198 to 432). In contrast to the manufacturer's
suggested ranges, the immunologic stable ranges in pediatric
cardiac recipients were very different. The authors concluded
that ICFA values during immunologic stability are related to
time from transplant in pediatric heart recipients; ICFA's ability
to discriminate rejection or infection from immunologic stability
was not demonstrated.
Ryan et al (2014) noted that management of pediatric renal
transplant patients involves multi-factorial monitoring
modalities to ensure allograft survival and prevent
opportunistic infection secondary to immunosuppression. An
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 23 of 48
ICFA, which utilizes CD4 T-cell production of ATP to assess
immune system status, has been used to monitor transplant
recipients and predict susceptibility of patients to rejection or
infection. However, the validity of this assay to reflect immune
status remains unanswered. In a 2-yr retrospective study that
included 31 pediatric renal transplant recipients, 42 patient
blood samples were analyzed for immune cell function levels,
creatinine, WBC (white blood cell) count, immunosuppressive
drug levels, and viremia, concurrent with renal biopsy. T-cell
ATP production as assessed by ICFA levels did not correlate
with allograft rejection or with the presence or absence of
viremia. ICFA levels did not correlate with serum creatinine or
immunosuppressive drug levels, but did correlate with WBC
count. The authors concluded that ICFA is unreliable in its
ability to reflect immune system status in pediatric renal
transplantation; further investigation is needed to develop
methods that will accurately predict susceptibility of pediatric
renal transplant recipients to allograft rejection and infection.
An UpToDate review on “Investigational methods in the
diagnosis of acute renal allograft rejection” (Chon and
Brennan, 2104) states that “The ImmuKnow assay is a US
Food and Drug Administration (FDA)-approved test intended
to estimate the net state of immune system in
immunocompromised patients. It measures the ability of CD4
cells to respond to mitogenic stimulation by
phytohemagglutinin-L in-vitro by quantifying the amount of
adenosine triphosphate (ATP) produced and released from
these cells following stimulation. At the present time, there is
no consensus on the utility of these tests, other than in the
research setting”.
Liu and colleagues (2014) stated that it is uncertain whether
ImmuKnow can predict the risk of infection in lupus nephritis
(LN) patients receiving immunosuppressive therapy. The
ImmuKnow Immune Cell Function Assay was applied to
measure the activity of CD4+ T cells, as a marker of global
immune-competence. The correlation between changes in T
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 24 of 48
cell activation and the relative risk of over-immunosuppression
as well as infection was studied. The amount of ATP
produced by CD4+ T cells in response to PHA was measured
for 74 LN patients without infection, 22 LN patients with severe
infection (i.e., required hospitalization), and 28 healthy
controls. No correlation was found between the ATP level and
systemic lupus erythematosus (SLE) activity. The mean ATP
level was significantly lower in LN patients with infection than
that in healthy controls (p < 0.01) and non-infected LN patients
(p < 0.01). The mean ATP level in non-infected LN patients
was not significantly different compared to healthy controls. A
cut-off ATP value of 300 ng/ml predicted infection in LN
patients with a specificity of 77 % and a sensitivity of 77 %.
Multi-variable partial correlation coefficient between the ATP
assay and severe infection was r = -0.040, p < 0.001; CRP
was r = 0.962, p < 0.001. The authors concluded that the
ImmuKnow assay may be effective in identifying an increased
risk of infection in LN patients but is not correlated with SLE
activity. Combined CRP value will increase the diagnostic rate
of severe infection in SLE. Moreover, they stated that larger
studies are needed to establish clinical advantages of this
assay in SLE treatment.
Ravaioli and colleagues (2015) observed that an immune
function assay shows promise for identifying solid organ
recipients at risk for infection or rejection. These investigators
conducted a randomized prospective study to assess the
clinical benefits of adjusting immunosuppressive therapy in
liver recipients based on ImmuKnow immune function assay
results. Adult liver recipients were randomized to standard
practice (control group; n = 102) or serial immune function
testing (interventional group; n = 100) performed with the
ImmuKnow assay before transplantation, immediately after
surgery and at day 1, weeks 1 to 4, 6, and 8, and months 3 to
6, 9, and 12. The assay was repeated within 7 days of
suspected/confirmed rejection/infection and within 1 week after
event resolution. Based on immune function values,
tacrolimus doses were reduced 25 % when values were less
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 25 of 48
than 130 ng/ml ATP (low immune cell response) and
increased 25 % when values were greater than 450 ng/ml ATP
(strong immune cell response). The 1-year patient survival
was significantly higher in the interventional arm (95 % versus
82 %; p < 0.01) and the incidence of infections longer than 14
days after transplantation was significantly lower among
patients in the interventional arm (42.0 % versus 54.9 %, p <
0.05). The difference in infection rates was because of lower
bacterial (32 % versus 46 %; p < 0.05) and fungal infection (2
% versus 11 %; p < 0.05). Among recipients without adverse
events, the study group had lower tacrolimus dosages and
blood levels. The authors concluded that ImmuKnow immune
function testing provided additional data which helped optimize
immunosuppression and improve patient outcomes.
Detection of Cellular Immune Function in Patients with Renal Cell Carcinoma
Zheng and colleagues (2015) examined the clinical value of
the CD4(+) T cell ATP levels in patients with renal cell
carcinoma through the application of the ImmuKnow assay.
These researchers recruited 104 patients with renal cancer
who had undergone surgery from March 2009 to June 2012,
and were subsequently treated by dendritic cell and cytokine
induced killer cell bio-therapy or interferon-alpha therapy. The
changes in CD4(+) T cell ATP levels were detected at the peri
operative period and at 10 days, 1 month, 3 months, and 1
year after the surgery using the ImmuKnow assay. In addition,
the differences in ATP levels in different therapy groups were
compared and the prognosis conditions were analyzed. The
results demonstrated that no significant difference in the ATP
levels occurred at different time-points. Furthermore, there
were no obviously different ATP levels between the different
therapy groups, and the ATP levels were found to have no
clinical significance for the assessment of renal cancer
prognosis. The authors concluded that the findings of this
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 26 of 48
study suggested that CD4(+) T cell ATP levels as detected by
the ImmuKnow assay have no obvious clinical value in
patients with renal cancer.
Monitoring the Immune Response Following Surgery
Maki and associates (2015) measured ATP levels in CD4+ T
cells as a marker of T-cell activity following surgery for
colorectal cancer using the ImmuKnow assay kit. A total of 16
consecutive patients who underwent surgical resection for
colorectal cancer between August and December, 2012 were
enrolled in this study, of whom 7 underwent laparoscopic
resection and 9 underwent open abdominal surgery. The
intracellular ATP levels in CD4+ T-lymphocytes were
measured using the ImmuKnow assay kit pre-operatively and
on the 1st, 4th and 8th post-operative days, as were the WBC
count, lymphocyte count and CRP levels. The ATP level of the
CD4+ T-cells was significantly elevated on the 1st day
following surgery compared to the pre-operative level (p <
0.01) and gradually returned to pre-operative levels; the
lymphocyte count was significantly decreased on the 1st post
operative day (p < 0.001). In addition, the ImmuKnow assay
demonstrated that only the ATP level, but not the WBC count,
lymphocyte count or CRP level, exhibited a significant
difference on the 1st (p = 0.080) and 8th (p = 0.042) post
operative days between the laparoscopic and open abdominal
surgery groups. The authors concluded that the ATP level of
CD4+ T-lymphocytes was increased in response to surgical
stress, in tandem with a decrease in the lymphocyte count.
The authors concluded that the ImmuKnow assay kit may be
clinically applicable for monitoring the immune response
following surgery, as it exhibited a higher sensitivity compared
to other assays. These findings need to be validated by well-
designed studies.
The Pleximmune Test
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 27 of 48
According to Plexision (Pittsburgh, PA), the Pleximmune test is
the only FDA-approved blood test that predicts rejection in
children with liver or intestine transplantation. The test
measures the risk of rejection by measuring the recipient's
immune response to the donor. The results are reported as an
individualized index; the sensitivity and specificity of this test
approaches or exceeds 80 %.
Sindhi and colleagues (2016) stated that the Pleximmune test
is the first cell-based test approved by the FDA, which predicts
acute cellular rejection in children with liver- or intestine
transplantation. The test addresses an unmet need to improve
management of immunosuppression, which incurs greater
risks of opportunistic infections and EBV-induced malignancy
during childhood. High-dose immunosuppression and
recurrent rejection after intestine transplantation also result in
a 5-year graft loss rate of up to 50 %. Such outcomes seem
increasingly unacceptable because children can experience
rejection-free survival with reduced immunosuppression. The
sensitivity and specificity of the Pleximmune test for predicting
acute cellular rejection are 84 % and 80 %, respectively in
training set-validation set testing of 214 children. Among
existing gold standards, the biopsy detects but cannot predict
rejection. Anti-donor antibodies, which presage antibody-
mediated injury, reflect late-stage allo-sensitization as a down
stream effect of engagement between recipient and donor
cells. Therefore, durable graft and patient outcomes also
require accurate management of cellular immune responses in
clinical practice.
An expert commentary of this review stated that “Alloantigen
specific CD154+T-cytotoxic memory cells (CD154+TcM)
measured in the Pleximmune blood test provide a
personalized measure of donor-specific cellular alloreactivity, a
universal mechanism of acute cellular rejection. Therefore, the
test system can potentially serve as a surrogate for this event,
and provide non-invasive detection or prediction of this event
in other organ systems … The potential of allospecific
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 28 of 48
CD154+TcM to detect acute cellular rejection in other organ
systems is illustrated by evaluation of 43 adult renal transplant
recipients. All subjects were sampled at the time of ‘for cause’
biopsies for allograft dysfunction. The IR of CD154+TcM,
which was associated with ongoing ACR in 32 of 43 training
set subjects demonstrated a sensitivity and specificity of 88 %
each. In the remaining subjects test sensitivity and specificity
of 100 % and 88 % replicated test performance confirming
additional uses of allospecific CD154+TcM. This experience
suggests that it will be possible to assess rejection-risk in adult
recipients using the principles of the test system described
here”.
Ashokkumar and associates (2017) noted that allospecific
CD154+TcM predicted acute cellular rejection after liver
transplantation (LTx) or intestine transplantation (ITx) in small
cohorts of children and can enhance immunosuppression
management, but await validation and clinical implementation.
To establish safety and probable benefit, these investigators
measured CD154+TcM in cryopreserved samples from 214
children younger than 21 years (National Clinical Trial
1163578). Training set samples (n = 158) were tested with
research-grade reagents and 122 independent validation set
samples were tested with current good manufacturing
practices-manufactured reagents after assay standardization
and reproducibility testing. Recipient CD154+TcM induced by
stimulation with donor cells were expressed as a fraction of
those induced by HLA non-identical cells in parallel cultures.
The resulting immunoreactivity index (IR) if greater than 1
implies increased rejection-risk. Training and validation set
subjects were demographically similar. Mean coefficient of
test variation was less than 10 % under several conditions.
Logistic regression incorporating several confounding
variables identified separate pre-transplant and post-transplant
IR thresholds for prediction of rejection in the respective
training set samples. An IR of 1.1 or greater in post-transplant
training samples and IR of 1.23 or greater in pre-transplant
training samples predicted LTx or ITx rejection in
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 29 of 48
corresponding validation set samples in the 60-day post-
sampling period with sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of 84 %, 80
%, 64 %, and 92 %, respectively (area under the receiver
operator characteristic curve, 0.792), and 57 %, 89 %, 78 %,
and 74 %, respectively (area under the receiver operator
characteristic curve, 0.848). No adverse events (AEs) were
encountered due to phlebotomy. The authors concluded that
allospecific CD154+T-cytotoxic memory cells predicted acute
cellular rejection after LTx or ITx in children; adjunctive use
can enhance clinical outcomes.
While the Pleximmune test results correlated with rejection,
they were based upon a small number of subjects in the FDA
labeling for the humanitarian device exemption (HDE) and a
published study, in which there were wide confidence intervals
for sensitivity, specificity as well as PPV and NPV.
Furthermore, there are currently no clinical outcome studies
(clinical utility) and no evidence-based guidelines supporting
the use of the Pleximmune test.
T-SPOT.CMV Test
According to Oxford Immunotec Inc., the T-SPOT.CMV test
measures the strength of T cell responses to CMV specific
antigens (Oxford Diagnostic Laboratories, 2018). The test
purportedly has the potential to help transplant patients and
physicians manage immune regulated conditions. The
T-SPOT.CMV test leverages Oxford Immunotec’s proprietary
T-SPOT technology platform. The new test are performed at
Oxford Diagnostic Laboratories in Memphis, TN, where
validation was performed. The test results are available to
customers within 2 days of receipt of a whole blood sample.
This test was developed and its performance characteristics
determined by Oxford Diagnostic Laboratories. It has not
been cleared or approved by the FDA. Oxford Diagnostic
Laboratories is regulated under the Clinical Laboratory
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 30 of 48
Improvement Amendments (CLIA) and the College of
American Pathologists (CAP) as an accredited laboratory to
perform high complexity clinical laboratory testing.
The measurement of CMV specific cellular immunity in organ
transplant recipients could contribute additional acuity to
serology based, CMV infection risk stratification, facilitating
optimization of immunosuppression and anti-viral prophylaxis
(Chanouzas, et al., 2018).
Chanouzas and colleagues (2018) conducted a pilot study of
renal transplant recipient (RTR's) responses in the
T-SPOT.CMV ELISPOT based assay. The investigators
recruited 108 RTR's 3 months post-transplantation,
immediately prior to the cessation of stratified anti-viral
prophylaxis, used in recipients from seropositive donors.
RTR's were monitored for CMV viremia and disease. Cellular
responses to peptides derived from CMV IE1 and pp65 were
measured, using the T-SPOT.CMV assay. At recruitment, no
CMV specific cellular immunity was detected by T-SPOT.CMV
in CMV seronegative recipients (IE1 ≤ 1spot / 2.5x105
PBMC's; pp65 ≤ 3 spots / 2.5x105 PBMC's). At recruitment,
CMV seropositive recipients who made a robust response to
both IE1 (>25 spots / 2.5x105 PBMC's) and pp65 (>50 spots /
2.5x105 PBMC's), were less likely to develop high level
viremia than those who responded to one or neither antigen
(0/28 vs 5/25; p<0.02). The authors concluded that, in CMV
seronegative RTR's, CMV specific cellular immunity measured
by T-SPOT.CMV was not detected prior to cessation of anti
viral prophylaxis. This differs from recent reports of CMV
specific cellular immunity in a proportion of CMV seronegative
RTR's, associated with protection from CMV infection. In
seropositive RTR's, a dual response to IE1 and pp65 at
recruitment, was associated with protection from subsequent
viremia. This suggests that assessing the diversity of response
to CMV antigens, may enhance risk stratification in this group.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 31 of 48
Cytomegalovirus (CMV) infection causes significant morbidity
and mortality after allogeneic hematopoietic cell
transplantation (allo-HCT). CMV management after HCT
includes risk stratification and mainly a preemptive strategy
with CMV viral load serial monitoring. Cell mediated immunity
(CMI) plays a role in CMV reactivation and can be assessed
by cytokine responses such as T cell production of interferon
gamma (IFN-γ). Quantification of CMV CMI may have value in
CMV management (Ariza-Heredia, et al., 2016).
Ariza-Heredia, et al. (2016) evaluated the potential of a CMV-
specific ELISPOT assay to determine CMI against CMV
reactivation in allo-HCT recipients ≤26 weeks post-HCT. This
is an ongoing, multi-center, prospective, observational study of
≥150 adult CMV seropositive allo-HCT recipients. CMV
management was according to institutional protocols. Date of
CMV reactivation, as defined by each institution, was
recorded. T cell responses were serially monitored pre-, and
every 2 weeks post-transplantation up to 26 weeks with an
ELISPOT assay that uses CMV-specific antigens IE-1 and
pp65 (T-SPOT.CMV, Oxford Diagnostics Laboratories®,
Memphis, TN). Data reviewed include patients reaching ≥12
weeks post-HCT by March 2016. Thirty-five patients across 6
sites reached ≥12 weeks post-HCT, and 15 reached ≥22
weeks. Majority of the patients were white (54%), males
(77%), with a median age of 57 (25–80) years, and had
unrelated (43%) or matched related (46%) HCT. CMV
reactivation occurred in 13 patients (37%) and time to first
reactivation occurred ≤10 weeks post-HCT. Average immune
response as measured by CMV-specific IE-1 and pp65 spot
counts (SPC) increased over time post-transplantation. The
preliminary analysis of the REACT study showed CMV
reactivation occurred early during transplantation when the
CMV immune response (measured by a CMV-specific
ELISPOT assay) was lower. In contrast, no reactivation was
seen later on when immune response was higher. This study
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 32 of 48
may provide insights into the CMV immune response which
may guide personalized decisions regarding CMV
management.
Gamma Interferon Response
Chandrashekaran and colleagues (2018) noted that the
number of lung transplantations performed worldwide
continues to increase. There is a growing need in these
patients for more effective immunosuppressive medications
with less toxicity. These researchers summarized the recent
studies and developments in lung transplant
immunosuppression. Novel immunosuppressive medications
and strategies used in other solid organ transplantations were
being tried in lung transplantation. This included the use of co-
stimulation blockers like belatacept and mTOR inhibitors like
everolimus. Calcineurin sparing regimens have been
described in an attempt to minimize nephrotoxicity. Assays to
measure the bioactivity of immunosuppressive medications to
determine the global immune competence, such as
ImmuKnow assay and gamma interferon response are gaining
traction. The authors concluded that immunosuppression in
lung transplant is evolving with the development of newer
drugs and promising strategies to optimize
immunosuppression. These researchers stated that further
studies with multi-center randomized trials are needed to
increase the strength of the evidence.
Measurement of Donor-Derived Cell-Free DNA as a Biomarker for Allograft Rejection in Solid Organ Transplantation
Beck and colleagues (2015) stated that in solid organ
transplantation, sensitive real-time biomarkers to evaluate the
graft health are desirable to enable early intervention (e.g., to
avoid full-blown rejections). During rejection, high amounts of
graft-derived cell-free DNA (GcfDNA) are shed into the blood
stream. The quantification of this GcfDNA in
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 33 of 48
allotransplantation is considered to fulfill this need, because it
can be measured with great precision and at reasonable cost.
In this study, patients from 2 ongoing studies in kidney (KTx)
and heart (HTx) transplantation were monitored blinded on a
scheduled basis, by means of a published universal droplet
digital PCR to quantify the GcfDNA. Immediately after
engraftment, GcfDNA reached high values (greater than 5 %
of total cfDNA), with a rapid decrease to values of less than
0.5 % within 1 week. Living-related KTx recipients showed
lower initial values, reflecting the absence of preservation
injury. Episodes of rejection in KTx and HTx were
accompanied by a significant increase of GcfDNA (greater
than 5-fold) above values in patients without complications,
occurring earlier than clinical or biochemical hints to rejection.
One case of rejection, which became clinically suspect after 1
year and was proven with biopsy, showed a significant 10-fold
increase 3 months earlier. The authors concluded that the
quantification of GcfDNA has the potential to detect rejection
episodes at early stages, when other means of diagnosis are
not effective. The method's non-invasiveness enables
monitoring of recipients at intervals that are desired to catch
rejections at early actionable stages to prevent full-blown
rejection. This biomarker will be particularly valuable in
regimens to minimize immunosuppression.
Sigdel and co-workers (2018) noted that standard non
invasive methods for detecting renal allograft rejection and
injury have poor sensitivity and specificity. Plasma donor-
derived cell-free DNA (dd-cfDNA) has been reported to
accurately detect allograft rejection and injury in transplant
recipients and shown to discriminate rejection from stable
organ function in KTx recipients. This study used a novel
single nucleotide polymorphism (SNP)-based massively
multiplexed PCR (mmPCR) methodology to measure dd
cfDNA in various types of KTx recipients for the detection of
allograft rejection/injury without prior knowledge of donor
genotypes. A total of 300 plasma samples (217 biopsy-
matched: 38 with active rejection (AR), 72 borderline rejection
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 34 of 48
(BL), 82 with stable allografts (STA), and 25 with other injury
(OI)) were collected from 193 unique KTx patients; dd- cfDNA
was processed by mmPCR targeting 13,392 SNPs. Median dd
cfDNA was significantly higher in samples with biopsy- proven
AR (2.3 %) versus BL (0.6 %), OI (0.7 %), and STA (0.4 %) (p
< 0.0001 all comparisons). The SNP-based dd- cfDNA assay
discriminated active from non-rejection status with an area
under the curve (AUC) of 0.87, 88.7 % sensitivity (95 % CI: 77.7
to 99.8 %) and 72.6 % specificity (95 % CI: 65.4 to 79.8 %) at a
pre-specified cut-off (greater than 1 % dd- cfDNA). Of 13
patients with AR findings at a routine protocol biopsy 6-month
post-KTx, 12 (92 %) were detected positive by dd-cfDNA. This
SNP-based dd-cfDNA assay detected allograft rejection with
superior performance compared with the current standard of
care (SOC). The authors concluded that these data supported
the feasibility of using this assay to detect disease prior to renal
failure and optimize patient management in the case of allograft
injury. They stated that this rapid, accurate, and non-invasive
technology allows for detection of significant renal injury in
patients better than the current SOC, with the potential for better
patient management, more targeted biopsies, and improved
renal allograft function and survival.
The authors stated that a drawback of this study was that it
was a retrospective analysis of archived samples from a
single-center. However, the central geographical area
enabled all biopsies to be performed by a single pathologist,
which may have helped minimize variability in biopsy
classification; further, all experimenters were kept blinded
during the process of data generation. The retrospective study
design may have led to differences in patient characteristics
across the rejection groups (e.g., the STA group was enriched
with younger patients who may be better suited
immunologically to tolerate transplanted organs compared to
older-aged patients). However, these age differences likely
did not affect the validity of the study findings.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 35 of 48
Whitlam and associates (2019) stated that GcfDNA (donor
derived cell-free DNA) is an emerging marker of kidney
allograft injury. Studies examining the clinical validity of this
biomarker have previously used the graft fraction, or
proportion of total cell-free DNA that is graft-derived. These
researchers evaluated the diagnostic validity of absolute
measurements of GcfDNA, as well as calculated graft fraction,
for the diagnosis of graft dysfunction. Plasma GcfDNA, total
cell-free DNA, and graft fraction were correlated with biopsy
diagnosis as well as individual Banff scores. A total of 61
samples were included in the analysis. For the diagnosis of
antibody mediated rejection (AMR), the receiver-operator
characteristic (ROC) AUC of GcfDNA and graft fraction were
0.91 (95 % CI: 0.82 to 0.98) and 0.89 (95 % CI: 0.79 to 0.98),
respectively. Both measures did not diagnose borderline or
type 1A cellular mediated rejection (CMR). Graft fraction was
associated with a broader range of Banff lesions, including
lesions associated with CMR, while GcfDNA appeared more
specific for AMR. The authors concluded that the capacity for
absolute quantification, and lower barriers to implementation of
this methodology recommend it for further study. They stated
that the drawbacks of this study included a small sample size
and lack of a validation cohort.
Huang and co-workers (2019) noted that dd-cfDNA became
Medicare reimbursable in the United States in October 2017
for the detection of rejection in KTx recipients based on results
from its pivotal validation trial, but it has not yet been externally
validated. These researchers evaluated 63 adult KTx
recipients with suspicion of rejection with dd-cfDNA and
allograft biopsy. Of these, 27 (43 %) patients had donor-
specific antibodies (DSA) and 34 (54 %) were found to have
rejection by biopsy. The percentage of dd-cfDNA was higher
among patients with AMR (median 1.35 %; interquartile range
[IQR]: 1.10 % to 1.90 %) compared to those with no rejection
(median 0.38 %, IQR: 0.26 % to 1.10 %; p < 0.001) and CMR
(median: 0.27 %, IQR: 0.19 % to 1.30 %; p = 0.01). The dd
cfDNA test did not discriminate patients with CMR from those
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 36 of 48
without rejection. The AUC for CMR was 0.42 (95 % CI: 0.17
to 0.66). For AMR, the AUC was 0.82 (95 % CI: 0.71 to 0.93)
and a dd-cfDNA greater than or equal to 0.74 % yielded a
sensitivity of 100 %, specificity 71.8 %, PPV 68.6 %, and NPV
100 %. The authors concluded that the dd-cfDNA test did not
discriminate CMR from no rejection among KTx recipients,
although performance characteristics were stronger for the
discrimination of AMR.
Khush and colleagues (2019) noted that standardized dd
cfDNA testing has been introduced into clinical use to monitor
KTx recipients for rejection. These investigators described the
performance of this dd-cfDNA assay to detect allograft
rejection in samples from HTx recipients undergoing
surveillance monitoring across the United States. Venous
blood was longitudinally sampled from 740 HT recipients from
26 centers and in a single-center cohort of 33 patients at high-
risk for AMR. Plasma dd-cfDNA was quantified by using
targeted amplification and sequencing of a SNP panel. The dd
cfDNA levels were correlated to paired events of biopsy- based
diagnosis of rejection. The median dd-cfDNA was 0.07
% in reference HTx recipients (2,164 samples) and 0.17 % in
samples classified as acute rejection (35 samples; p = 0.005).
At a 0.2 % threshold, dd-cfDNA had a 44 % sensitivity to
detect rejection and a 97 % NPV. In the cohort at risk for AMR
(11 samples), dd-cfDNA levels were elevated 3-fold in AMR
compared with patients without AMR (99 samples, p = 0.004).
The standardized dd-cfDNA test identified acute rejection in
samples from a broad population of HTx recipients. The
authors concluded that the reported test performance
characteristics will guide the next stage of clinical utility studies
of the dd-cfDNA assay.
Oellerich and co-workers (2019) noted that dd-cfDNA is a non
invasive biomarker for comprehensive monitoring of allograft
injury and rejection in KTx. dd-cfDNA quantification of
copies/ml plasma (dd-cfDNA[cp/ml]) was compared to dd
cfDNA fraction (dd-cfDNA[%]) at pre-specified visits in 189
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 37 of 48
patients over 1 year post-KTx. In patients (N = 15, n = 22
samples) with biopsy-proven rejection (BPR), median dd
cfDNA(cp/ml) was 3.3-fold and median dd-cfDNA(%) 2.0-fold
higher (82 cp/ml; 0.57 %, respectively) than medians in Stable
Phase patients (N = 83, n = 408) without rejection (25 cp/ml;
0.29 %). Results for acute tubular necrosis (ATN) were not
significantly different from those with BPR. dd-cfDNA
identified unnecessary biopsies triggered by a rise in plasma
creatinine; ROC analysis showed superior performance (p =
0.02) of measuring dd-cfDNA(cp/ml) (AUC = 0.83) compared
to dd-cfDNA(%) (AUC = 0.73). Diagnostic odds ratios (DORs)
were 7.31 for dd-cfDNA(cp/ml), and 6.02 for dd-cfDNA(%) at
thresholds of 52 cp/ml and 0.43 %, respectively. Plasma
creatinine showed a low correlation (r = 0.37) with dd-cfDNA
(cp/ml). In a patient subset (N = 24) there was a significantly
higher rate of patients with elevated dd-cfDNA(cp/ml) with
lower tacrolimus levels (less than 8 μg/L) compared to the
group with higher tacrolimus concentrations (p = 0.0036)
suggesting that dd-cfDNA may detect inadequate
immunosuppression resulting in subclinical graft damage.
Absolute dd-cfDNA(cp/ml) allowed for better discrimination
than dd-cfDNA(%) of KTx patients with BPR and is useful to
avoid unnecessary biopsies.
The authors stated that drawbacks of this study included the
lack of protocol biopsies and the fact that the vast majority of
patients were of Caucasian origin. The findings from this study
support the role of dd‐cfDNA as a pivotal addition to the
methods currently used to achieve personalized
immunosuppression in KTx, such as immunological
monitoring, therapeutic drug monitoring, microbial screening,
and biopsy. Based on all this information, in agreement with
other reports, these researchers are confident that dd‐cfDNA
can be recommended for clinical translation as a valid tool to
aid personalized patient care for the benefit of transplanted
patients and healthcare payers. To achieve this, methods
providing a fast turn-around time, such as the ddPCR used
herein, will allow frequent monitoring and provide actionable
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 38 of 48
results (e.g., to aid in decision‐making for biopsy).
CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":
Code Code Description
ImmuKnow Assay:
CPT codes covered if selection criteria are met:
86352 Cellular function assay involving stimulation
(eg, mitogen or antigen) and detection of
biomarker (EG, ATP)
Other CPT codes related to the CPB:
38240 Hematopoietic progenitor cell (HPC); allogeneic
transplantation per donor
ICD-10 codes covered if selection criteria are met:
A00.0 -
B99.9
Infectious and parasitic diseases
C00.0 -
D09.9
Malignant neoplasms [not covered for detection
of cellular immune function in individuals with
renal cell carcinoma]
T45.1X5+ Adverse effect of antineoplastic and
immunosuppressive drugs
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
D47.z1 Post-transplant lymphoproliferative disorder
(PTLD)
D89.810 -
D89.813
Graft-versus-host disease
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 39 of 48
Code Code Description
K50.00 -
K50.019
Crohn's disease
K51.00 -
K51.919
Ulcerative colitis
M32.14 Glomerular disease in systemic lupus
erythematosus [Lupus nephritis]
T86.10 -
T86.819
T86.890 -
T86.899
Complications of transplanted organ
Z48.21 -
Z48.298
Aftercare following organ transplant
Z48.3 Aftercare following surgery for neoplasm
[monitoring the immune response following
surgery]
Z48.810 -
Z48.89
Encounter for other specified postprocedural
aftercare [monitoring the immune response
following surgery]
Z76.82 Awaiting organ transplant status
Other Transplantation Immune Cell Function Assay:
CPT codes not covered for indications listed in the CPB:
T-SPOT.CMV, gamma interferon response for measurement of the bioactivity of immunosuppressive medications in lung transplantation - no specific code:
0118U Transplantation medicine, quantification of
donor-derived cell-free DNA using whole
genome next-generation sequencing, plasma,
reported as percentage of donor-derived cell-
free DNA in the total cell-free DNA
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 40 of 48
Code Code Description
T86.10 -
T86.49
T86.810 -
T86.819
T86.850 -
T86.99
Complications of transplanted organ
Z94.0 Kidney transplant status
Z94.1 Heart transplant status
Z94.2 Lung transplant status
Z94.3 Heart and lungs transplant status
Z94.4 Liver transplant status
Z94.83 Pancreas transplant status
The above policy is based on the following references:
1. Kowalski RJ, Post DR, Mannon RB, et al. Assessing
relative risks of infection and rejection: A meta-analysis
using an immune function assay. Transplantation. 2006;
82(5):663-668.
2. Thai NL, Blisard D, Tom K, et al. Pancreas
transplantation under alemtuzumab (Campath-1H) and
tacrolimus: Correlation between low T-cell responses and
infection. Transplantation. 2006;82(12):1649-1652.
3. Cadillo-Chávez R, de Echegaray S, Santiago-Delpín EA,
et al. Assessing the risk of infection and rejection in
Hispanic renal transplant recipients by means of an
adenosine triphosphate release assay. Transplant Proc.
2006;38(3):918-920.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 41 of 48
4. Huang Y, Nizami Nazih Zuhdi I. Correlation of Cylex
ImmuKnow assay with lung allograft biopsy. J Heart Lung
Transplant. 2007;26:S175.
5. Bhorade SM, Janata K, Vigneswaran WT, et al. Cylex
ImmuKnow assay levels are lower in lung transplant
recipients with infection. J Heart Lung Transplant.
2008;27(9):990-994.
6. Sampson VB, Dunn SP, Rymeski B, et al. Failure of
immunosuppressive drug levels to predict T-cell reactivity
in pediatric transplant patients. J Pediatr Surg. 2008;43
(6):1134-1141.
7. Batal I, Zeevi A, Heider A, et al. Measurements of global
cell-mediated immunity in renal transplant recipients with
BK virus reactivation. Am J Clin Pathol. 2008;129(4):587
591.
8. Gupta S, Mitchell JD, Markham DW, et al. Utility of the
Cylex assay in cardiac transplant recipients. J Heart Lung
Transplant. 2008;27(8):817-822.
9. U.S. Food and Drug Administration (FDA). Cylex Immune
Cell Function Assay. 510(k) Summary. K013169.
Rockville, MD: FDA; April 2, 2002.
10. Cylex Inc. ImmuKnow [website]. Columbia, MD: Cylex;
2008. Available at:
http://www.cylex.net/index.html. Accessed October 28,
2008.
11. Humar A, Michaels M; AST ID Working Group on
Infectious Disease Monitoring. American Society of
Transplantation recommendations for screening,
monitoring and reporting of infectious complications in
immunosuppression trials in recipients of organ
transplantation. Am J Transplant. 2006; 6(2):262-274.
12. Indiana University School of Medicine. Investigation of
the Cylex ImmuKnow Assay. ClinicalTrials.gov Identifier
NCT00569842. Bethesda, MD: National Library of
Medicine; updated July 30, 2008.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 42 of 48
13. Cylex Inc. Cylex announces plans for multi-center trial of
ImmuKnow Assay in South Korea. Press Release.
Columbia, MD: Cylex; August 28, 2008.
14. Chon WJ, Brennan DC. Investigational methods in the
diagnosis of acute renal allograft rejection. UpToDate
[online serial]. Waltham, MA: UpToDate; October 2009.
15. Serban G, Whittaker V, Fan J, et al. Significance of
immune cell function monitoring in renal transplantation
after Thymoglobulin induction therapy. Hum Immunol.
2009;70(11):882-890.
16. Cabrera R, Ararat M, Soldevila-Pico C, et al. Using an
immune functional assay to differentiate acute cellular
rejection from recurrent hepatitis C in liver transplant
patients. Liver Transpl. 2009;15(2):216-222.
17. Husain S, Raza K, Pilewski JM, et al. Experience with
immune monitoring in lung transplant recipients:
Correlation of low immune function with infection.
Transplantation. 2009;87(12):1852-1857.
18. Macedo C, Zeevi A, Bentlejewski C, et al. The impact of
EBV load on T-cell immunity in pediatric thoracic
transplant recipients. Transplantation. 2009;88(1):123
128.
19. Rossano JW, Denfield SW, Kim JJ, et al. Assessment of
the Cylex ImmuKnow cell function assay in pediatric
heart transplant patients. J Heart Lung Transplant.
2009;28(1):26-31.
20. Martinu T, Chen DF, Palmer SM. Acute rejection and
humoral sensitization in lung transplant recipients. Proc
Am Thorac Soc. 2009;6(1):54-65.
21. Gesundheit B, Budowski E, Israeli M, et al. Assessment
of CD4 T-lymphocyte reactivity by the Cylex ImmuKnow
assay in patients following allogeneic hematopoietic SCT.
Bone Marrow Transplant. 2010;45(3):527-533.
22. Bennett WM, Meyer L, Ridenour J, Batiuk TD.
Surveillance and modification of immunosuppression
minimizes BK virus nephropathy. Am J Nephrol. 2010;32
(1):10-12.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 43 of 48
23. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of
immune monitoring in heart transplant patients using ATP
production in activated lymphocytes. J Heart Lung
Transplant. 2010;29(5):504-508.
24. Torío A, Fernández E, Montes-Ares O, et al. Lack of
association of immune cell function test with rejection in
kidney transplantation. Transplant Proc. 2011;43
(6):2168-2170.
25. De Paolis P, Favarò A, Piola A, et al. "Immuknow" to
measurement of cell-mediated immunity in renal
transplant recipients undergoing short-term evaluation.
Transplant Proc. 2011;43(4):1013-1016.
26. Huskey J, Gralla J, Wiseman AC. Single time point
immune function assay (ImmuKnow) testing does not aid
in the prediction of future opportunistic infections or acute
rejection. Clin J Am Soc Nephrol. 2011;6(2):423-429.
27. Cheng JW, Shi YH, Fan J, et al. An immune function
assay predicts post-transplant recurrence in patients with
hepatocellular carcinoma. J Cancer Res Clin Oncol.
2011;137(10):1445-1453.
28. Ling X, Xiong J, Liang W, et al. Can immune cell function
assay identify patients at risk of infection or rejection? A
meta-analysis. Transplantation. 2012;93(7):737-743.
29. Shino MY, Weigt SS, Saggar R, et al. Usefulness of
immune monitoring in lung transplantation using
adenosine triphosphate production in activated
lymphocytes. J Heart Lung Transplant. 2012;31(9):996
1002.
30. Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow(®)
as a diagnostic tool for predicting infection and acute
rejection in adult liver transplant recipients: Systematic
review and meta-analysis. Liver Transpl. 2012;18
(10):1245-1253.
31. Akimoto M, Yunoue S, Otsubo H, et al. Assessment of
peripheral blood CD4+ adenosine triphosphate activity in
patients with rheumatoid arthritis. Mod Rheumatol.
2013;23(1):19-27.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 44 of 48
32. Lopez-Hoyos M, Rodrigo E, Arias M. The usefulness of
intracellular adenosine-5'-triphosphate measurement in
CD4+ cells in renal transplant. Nefrologia. 2013;33
(3):381-388.
33. Israeli M, Klein T, Herscovici C, et al. Cellular immune
function monitoring after allogeneic haematopoietic cell
transplantation: Evaluation of a new assay. Clin Exp
Immunol. 2013;172(3):475-482.
34. Brandhorst G, Weigand S, Eberle C, et al. CD4+ immune
response as a potential biomarker of patient reported
inflammatory bowel disease (IBD) activity. Clin Chim
Acta. 2013;421:31-33.
35. Wong MS, Boucek R, Kemna M, et al. Immune cell
function assay in pediatric heart transplant recipients.
Pediatr Transplant. 2014;18(5):485-490.
36. Ryan CM, Chaudhuri A, Concepcion W, Grimm PC.
Immune cell function assay does not identify biopsy-
proven pediatric renal allograft rejection or infection.
Pediatr Transplant. 2014;18(5):446-452.
37. Chon WJ, Brennan DC. Investigational methods in the
diagnosis of acute renal allograft rejection. UpToDate
[online serial]. Waltham, MA: UpToDate; reviewed July
2014.
38. Liu J, Pan Y, Tang LJ, et al. Low adenosine triphosphate
activity in CD4+ cells predicts infection in patients with
lupus nephritis. Clin Exp Rheumatol. 2014;32(3):383-389.
39. Ravaioli M, Neri F, Lazzarotto T, Bertuzzo VR, et al.
Immunosuppression modifications based on an
immune response assay: Results of a randomized,
controlled trial. Transplantation. 2015;99(8):1625-1632.
40. Andreotti C, Zortea M, Provenzani A, et al. Immuknow
and long term kidney graft. G Ital Nefrol. 2015;32(2).
41. Jwa E, Hwang S, Kwon YJ, et al. In vitro immune cell
monitoring as a guide for long-term
immunosuppression in adult liver transplant
recipients. Korean J Hepatobiliary Pancreat Surg.
2015;19(4):139-148.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 45 of 48
42. Zheng K, Zhang JP, Tan JM, et al. Lack of clinical
significance of the ImmuKnow(TM)-Cylex assay for the
detection of cellular immune function in patients with
renal cell carcinoma. Genet Mol Res. 2015;14(3):11543-
11550.
43. Maki K, Takeno S, Aisu N, et al. CD4+ T-lymphocytes
are activated by surgical stress following colorectal
resection in cancer patients. Mol Clin Oncol. 2015;3
(1):79-82.
44. Zhang W, Zhong H, Zhuang L, et al. Peripheral blood
CD4(+) cell ATP activity measurement to predict HCC
recurrence post-DCD liver transplant. Int J Clin Pract.
2016;70 Suppl 185:11-16.
45. Sindhi R, Ashokkumar C, Higgs BW, et al. Profile of the
Pleximmune blood test for transplant rejection risk
prediction. Expert Rev Mol Diagn. 2016;16(4):387-393.
46. Ashokkumar C, Soltys K, Mazariegos G, et al. Predicting
cellular rejection with a cell-based assay: Preclinical
evaluation in children. Transplantation. 2017;101
(1):131-140.
47. Chiereghin A, Petrisli E, Ravaioli M, et al. Infectious
agents after liver transplant: Etiology, timeline and
patients' cell-mediated immunity responses. Med
Microbiol Immunol. 2017;206(1):63-71.
48. Schmidt T, Schub D, Wolf M, et al. Comparative
analysis of assays for detection of cell-mediated
immunity toward cytomegalovirus and M. tuberculosis
in samples from deceased organ donors. Am J
Transplant. 2014;14(9):2159-2167.
49. Luo Y, Ji WB, Duan WD, et al. Delayed introduction of
immunosuppressive regimens in critically ill patients
after liver transplantation. Hepatobiliary Pancreat Dis
Int. 2017;16(5):487-492.
50. Chanouzas D, Small A, Borrows R, Ball S. Assessment
of the T-SPOT.CMV interferon-γ release assay in renal
transplant recipients: A single center cohort study.
PLoS One. 2018;13(3):e0193968.
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 46 of 48
51. Ariza-Heredia E, Shah DP, El Chaer F, et al. Prospective
observational study to evaluate a cytomegalovirus
(CMV)–specific T-SPOT assay in hematopoietic stem
cell transplant recipients: The REACT Study interim
data review. Open Forum Infect Dis. 2016; 3 (Suppl 1):
2297.
52. Oxford Diagnostic Laboratories. The T-Spot.CMV test
[website]. Abingdon, UK: Oxford Immunotec; 2018.
Available at:
http://www.oxforddiagnosticlabs.com/products-and-
services/t-spot-cmv/. Accessed August 19, 2018.
53. Chandrashekaran S, Crow Pharm SA, Shah SZ, et al.
Immunosuppression for lung transplantation: Current
and future. Curr Transplant Rep. 2018;5(3):212-219.
54. Beck J, Oellerich M, Schulz U, et al. Donor-derived cell-
free DNA Is a novel universal biomarker for allograft
rejection in solid organ transplantation. Transplant
Proc. 2015;47(8):2400-2403.
55. Sigdel TK, Archila FA, Constantin T, et al. Optimizing
detection of kidney transplant injury by assessment of
donor-derived cell-free DNA via massively multiplex
PCR. J Clin Med. 2018;8(1).
56. Whitlam JB, Ling L, Skene A, et al. Diagnostic
application of kidney allograft-derived absolute cell-
free DNA levels during transplant dysfunction. Am J
Transplant. 2019;19(4):1037-1049.
57. Huang E, Sethi S, Peng A, et al. Early clinical experience
using donor-derived cell-free DNA to detect rejection
in kidney transplant recipients. Am J Transplant.
2019;19(6):1663-1670.
58. Khush KK, Patel J, Pinney S, et al. Noninvasive
detection of graft injury after heart transplant using
donor-derived cell-free DNA: A prospective multicenter
study. Am J Transplant. 2019 Mar 5 [Epub ahead of
print].
59. Oellerich M, Shipkova M, Asendorf T, et al. Absolute
quantification of donor-derived cell-free DNA as a
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 47 of 48
marker of rejection and graft injury in kidney
transplantation: Results from a prospective
observational study. Am J Transplant. 2019 May 7
[Epub ahead of print].
Proprietary
Transplant Immune Cell Function Assays - Medical Clinical Policy Bulletins | Aetna Page 48 of 48
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan
benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial,
general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care
services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors
in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely
responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is
subject to change.
Copyright © 2001-2020 Aetna Inc.
Proprietary
AETNA BETTER HEALTH® OF PENNSYLVANIA
Amendment to Aetna Clinical Policy Bulletin Number: 0773 Transplant
Immune Cell Function Assays
There are no amendments for Medicaid.
www.aetnabetterhealth.com/pennsylvania annual 10/01/2020
Proprietary Proprietary